Journal article · 2026 · Open access

Optimal strategies for treatment discontinuation in MOG antibody-associated disease

Wei Zhen Yeh, Anna G. Francis, Sarah Anne Cooper, Waqar Rashid, Roswell J. Martin, Jeremy Hobart, Christopher A. Halfpenny, Victoria Williams, Eoin O’Sullivan, Cheryl A Hemingway, Yael Hacohen, Dobson Ruth and 7 more

Brain, 149(9), 3242–3253 · Published 9 January 2026 · DOI 10.1093/brain/awag006

Open full textCite this paper

In brief

“Optimal strategies for treatment discontinuation in MOG antibody-associated disease” is a 2026 journal article by Wei Zhen Yeh and 18 co-authors, published in Brain. OpenAlex counts 11 citations as of 17 November 2026. It is open access under a CC BY licence: the full text is free to read at Brain.

Citations
11
Most cited in
2026 (10)
Field-weighted impact
29.72
References
34
Authors
19

Abstract

The relapse risk following discontinuation of immunomodulatory treatment in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is unknown. Evidence suggests that 'at least' 3 months of oral corticosteroids reduces relapse risk after a single attack, and that it may be possible to stop maintenance treatment in relapsing stable disease, but the optimal duration of treatment has yet to be defined. We therefore investigated relapse outcomes following discontinuation of maintenance treatment. We conducted a cohort study of MOGAD patients seen in the Oxford Neuromyelitis Optica Highly Specialised Service between January 2010 and May 2025. Patients with MOGAD who had at least 12 months of follow-up and who commenced and then discontinued maintenance treatment were included. Associations of factors including treatment duration before discontinuation, disease course at discontinuation (after a single attack/monophasic or relapsing course) and MOG IgG1 status on live cell-based assay were investigated. The primary outcome was time-to-relapse following treatment discontinuation. Cox regression was used. We included 190 MOGAD patients with 236 discontinued treatment intervals. There were 150 (63.6%) discontinuations after a single attack and before a first relapse in patients with monophasic disease, and 86 (36.4%) discontinuations in patients with relapsing disease. Most patients used corticosteroids alone [84.7% of immunomodulatory treatment (IT) intervals], and non-steroid ITs were used in 15.2% of IT intervals, either alone or in combination with steroids. Post-discontinuation relapse occurred after 92 (39.0%) discontinuations, at a median time of 5.4 (interquartile range 1.4-20.1) months after treatment cessation. Those who relapsed were more likely to have a relapsing course at the time of discontinuation (50% versus 27.8%, P = 0.001) and a positive/low-positive pre-discontinuation MOG IgG1 result (89.8% versus 71.5%, P = 0.005). In a multivariable analysis, a relapsing course at the time of discontinuation was associated with an elevated relapse risk (hazard ratio 1.95, 95% confidence interval 1.25-3.06, P = 0.003). Overall, prolonged treatment beyond 3 months before discontinuation significantly reduced relapse risk. Optimal treatment durations were estimated to be 10-18 months for patients treated after their first attack and 20-30 months for relapsing patients, after which treatment discontinuation could be considered in patients who were relapse-free on treatment. Identifying the relapse risk when discontinuing maintenance immunomodulatory treatment in MOGAD should aid management decisions in patients presenting with their first attack and also in those on longer-term treatment for relapsing disease. Our findings, from a cohort predominantly treated with steroids, provide evidence to inform joint decision-making for stable patients who are considering treatment cessation.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Yeh, W. Z., Francis, A. G., Cooper, S. A., Rashid, W., Martin, R. J., Hobart, J., Halfpenny, C. A., Williams, V., O’Sullivan, E., Hemingway, C. A., Hacohen, Y., Ruth, D., Waters, P. J., Sharma, S. M., Butzkueven, H., Geraldes, R., Ramdas, S., Leite, M. I., & Palace, J. A. (2026). Optimal strategies for treatment discontinuation in MOG antibody-associated disease. Brain, 149(9), 3242–3253. https://doi.org/10.1093/brain/awag006

MLA 9

Yeh, Wei Zhen, et al. “Optimal strategies for treatment discontinuation in MOG antibody-associated disease.” Brain, vol. 149, no. 9, 2026, pp. 3242–3253. https://doi.org/10.1093/brain/awag006.

Chicago

Yeh, Wei Zhen, Anna G. Francis, Sarah Anne Cooper, Waqar Rashid, Roswell J. Martin, Jeremy Hobart, Christopher A. Halfpenny, et al. 2026. “Optimal strategies for treatment discontinuation in MOG antibody-associated disease.” Brain 149 (9): 3242–3253. https://doi.org/10.1093/brain/awag006.

Harvard

Yeh, W. Z. et al. (2026) ‘Optimal strategies for treatment discontinuation in MOG antibody-associated disease’, Brain, 149(9), pp. 3242–3253. doi:10.1093/brain/awag006.

IEEE

W. Z. Yeh et al., “Optimal strategies for treatment discontinuation in MOG antibody-associated disease,” Brain, vol. 149, no. 9, pp. 3242–3253, 2026, doi: 10.1093/brain/awag006.

BibTeX

@article{yeh2026optimal,
  title     = {{Optimal strategies for treatment discontinuation in MOG antibody-associated disease}},
  author    = {Yeh, Wei Zhen and Francis, Anna G. and Cooper, Sarah Anne and Rashid, Waqar and Martin, Roswell J. and Hobart, Jeremy and Halfpenny, Christopher A. and Williams, Victoria and O’Sullivan, Eoin and Hemingway, Cheryl A and Hacohen, Yael and Ruth, Dobson and Waters, Patrick Joseph and Sharma, Srilakshmi M. and Butzkueven, Helmut and Geraldes, Ruth and Ramdas, Sithara and Leite, Maria Isabel and Palace, Jacqueline A.},
  journal   = {Brain},
  year      = {2026},
  volume    = {149},
  number    = {9},
  pages     = {3242--3253},
  doi       = {10.1093/brain/awag006},
  url       = {https://doi.org/10.1093/brain/awag006}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies

  • myelin oligodendrocyte glycoprotein antibody-associated disease
  • MOGAD
  • treatment discontinuation
  • relapse risk
  • oral corticosteroids
  • live cell-based assay
  • relapsing disease course
  • time to relapse

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Yeh, W. Z., Francis, A. G., Cooper, S. A., Rashid, W., Martin, R. J., Hobart, J., Halfpenny, C. A., Williams, V., O’Sullivan, E., Hemingway, C. A., Hacohen, Y., Ruth, D., Waters, P. J., Sharma, S. M., Butzkueven, H., Geraldes, R., Ramdas, S., Leite, M. I., & Palace, J. A. (2026). Optimal strategies for treatment discontinuation in MOG antibody-associated disease. Brain, 149(9), 3242–3253. https://doi.org/10.1093/brain/awag006

How many times has this paper been cited?

11 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Brain: sign in and open the full text from this page.

Who wrote this paper?

Wei Zhen Yeh, Anna G. Francis, Sarah Anne Cooper, Waqar Rashid, Roswell J. Martin, Jeremy Hobart, Christopher A. Halfpenny, Victoria Williams, Eoin O’Sullivan, Cheryl A Hemingway, Yael Hacohen, Dobson Ruth and 7 more.

What is the DOI of this paper?

10.1093/brain/awag006, permanently at https://doi.org/10.1093/brain/awag006. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.